Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test. Issue 1 (24th December 2012)

• Record Type: Journal Article
• Authors: Vázquez‐Ortiz, M.; Álvaro‐Lozano, M.; Alsina, L.; Garcia‐Paba, M. B.; Piquer‐Gibert, M.; Giner‐Muñoz, M. T.; Lozano, J.; Domínguez‐Sánchez, O.; Jiménez, R.; Días, M.; Martín‐Mateos, M. A.; Plaza‐Martín, A. M.
• Is Part Of: Clinical & experimental allergy. Volume 43:Issue 1(2013:Jan.)
• Page Start: 92
• Page End: 102
• Publication Date: 2012-12-24
• Subjects: anaphylaxis -- cow's milk allergy -- cow's milk sIgE -- cow's milk skin prick test -- food allergy -- omalizumab -- oral desensitization -- oral immunotherapy -- safety -- specific oral tolerance induction -- survival analysis; Allergy -- Periodicals; Immunology -- Periodicals; 616.97
• DOI: 10.1111/cea.12012
• Languages: English
• ISSNs: 0954-7894

Abstract

Summary: Background: Strict avoidance is the only accepted management for cow's milk (CM) allergy. CM oral immunotherapy (CM‐OIT) is under investigation. Objectives: To evaluate long‐term safety of CM‐OIT. To identify clinical/immunological predictors of adverse events. Methods: Prospective longitudinal epidemiological intervention study. CM‐allergic children aged 5–18 underwent a Spanish‐approved CM‐OIT protocol without premedication. Clinical data, skin prick test (SPT) and specific IgE (sIgE) at baseline and 1 year after OIT were registered. All dose‐related reactions, treatments needed and cofactors involved were recorded. Through survival analysis, we studied the cumulative probability of reactions resolution over time and clinical/immunological risk factors of reactions persistence. Results: 81 children were recruited. Mean follow‐up was 25 months. 95% of children suffered reactions, 91% of which affected a single organ. Reactions were heterogeneously distributed: (a) 60 children (75%) had occasional symptoms which ceased over time. 86% of them reached complete desensitization (200 mL). (b) 20 children (25%) suffered frequent (78% of total reactions), more severe and unpredictable reactions, which persisted during follow‐up or led to withdrawal (6 cases). Reactions persistence was associated with a higher frequency and severity. Kaplan–Meier estimate revealed a cumulative probability of reactions resolution of 25% at 3 months (95% CI: 1.9–4.1) and 50% (95% CI: 6.1–9.9) at 8 months based on all patients. Cox proportional hazards multivariate regression model identified 3 variables (CM‐sIgE ≥ 50 KU L −1, CM‐SPT ≥ 9 mm and Sampson's severity grades 2, 3 and 4 at baseline food challenge) as independent risk factors of reactions persistence. The combination of 2 or 3 of these factors involved hazard ratios to develop persistent reactions of 2.26 (95% CI: 1.14–4.46; P = 0.019) and 6.06 (95% CI: 2.7–13.7; P < 0.001), respectively. Clinical implications: CM‐OIT was insufficiently safe in 25% of children. The above‐mentioned clinical and immunological parameters would help clinicians to identify highly reactive patients before CM‐OIT. In them, individualized schedules and premedication should be considered.